Henderson Morley plc

Henderson Morley plc is engaged in the development of drugs and vaccines for the pharmaceutical industry. The Company has a pipeline of clinical and pre-clinical candidates in a range of disease areas, including skin warts; verrucae (warts on the feet and toes); herpes simplex infections of the mouth and genitalia, and eyes; adenovirus infection of the eyes, and recurrent respiratory papillomatosis (RRP). It also has vaccine development programme targeted at viruses, which include herpes simplex, cytomegalovirus and Epstein Barr Virus. The PREPS and L-particles technology is being developed as an immunotherapy for various forms of cancer in both humans and companion animals. It is developing laboratory reagents using marker viruses and vaccine adjuvants.